Search for European Projects

Over 40 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Crimean-Congo Haemorrhagic Fever Vaccine (CCHFVaccine)

Start date: Jan 1, 2017, End date: Dec 31, 2022,

Natural epidemics and outbreaks of emerging viral epidemics are growing problems internationally. The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) disease on a global basis. The proposed work program on CCHF virus aims to build a multidisciplinary researc...
Read Project

 15

 FINISHED 

Illuminating GENome Organization through integrated MIcroscopy and Sequencing (GENOMIS)

Start date: Jan 1, 2018, End date: Dec 31, 2022,

In human cells, two meters of DNA sequence are compressed into a nucleus whose linear size is five orders of magnitude smaller. Deciphering how this amazing structural organization is achieved and how DNA functions can ensue in the environment of a cell’s nucleus represent central questions for contemporary biology.Here, I embrace this challenge by establishing a comprehensive framework of microsc...
Read Project

 1

 FINISHED 

Chromatin dynamics resolved by rapid protein labeling and bioorthogonal capture (RAPID)

Start date: Jan 1, 2017, End date: Dec 31, 2021,

Histone proteins provide a dynamic packaging system for the eukaryotic genome. Chromatin integrates a multitude of signals to control gene expression, only some of which have the propensity to be maintained through replication and cell division. For our understanding of cellular memory and epigenetic inheritance we need to know what features characterize a stable, heritable chromatin state through...
Read Project

 1

 FINISHED 

European Sudden Cardiac Arrest network: towards Prevention, Education and NEw Treatment (ESCAPE-NET)

Start date: Jan 1, 2017, End date: Dec 31, 2021,

Sudden cardiac arrest (SCA) causes ~20% of all deaths in Europe. SCA is lethal within minutes if left untreated and survival rates are presently only 5-20%. Therefore, there is a large medical need to improve SCA prevention and treatment. Designing effective individualized prevention and treatment strategies requires knowledge on genetic and environmental risk factors. So far, these efforts have b...
Read Project

 17

 FINISHED 

Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine (MultipleMS)

Start date: Jan 1, 2017, End date: Dec 31, 2021,

The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations.MultipleMS will therefor...
Read Project

 25

 FINISHED 

An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk)

Start date: Jan 1, 2016, End date: Dec 31, 2021,

The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi...
Read Project

 43

 FINISHED 

Exploration and promotion of neurogenesis in the adult brain (Neurogenesis)

Start date: Oct 1, 2016, End date: Sep 30, 2021,

It is now well established that new neurons are added to certain regions of the adult brain. There is today considerable interest in the development of regenerative therapies based on modulating endogenous neurogenesis, but it is necessary to better understand these events to assess whether this is rational and realistic. This application takes its initiation in two recent discoveries that we have...
Read Project

 1

 FINISHED 

Children and Adolescents with PaRental mental Illness: Understanding the ‘who’ and ‘how’ of targeting interventions (CAPRI)

Start date: Oct 1, 2016, End date: Sep 30, 2021,

At least 10% of mothers and 5% of fathers have a mental illness. Family, educational and social lives of children and adolescents with parental mental illness (CAPRI) are disrupted by deprivation and repeated hospitalisation. This is an urgent political and public health concern. The Child and Adolescent Mental Health in Europe (CAMHEE) report urges us ‘to acknowledge and attend to the needs of ch...
Read Project

 2

 FINISHED 

Restoration of tumor suppressor function by induction of translational read-through of premature termination codons - a strategy for improved cancer therapy (TRANSREAD)

Start date: Sep 1, 2016, End date: Aug 31, 2021,

Tumor suppressor genes such as TP53, RB1, PTEN and APC are frequently inactivated in sporadic and inherited human tumors. A significant fraction of the mutations in these genes are nonsense mutations that lead to premature termination of translation and expression of truncated unstable and non-functional proteins. We will identify and characterize novel molecules that can induce translational read...
Read Project

 1

 FINISHED 

Reversing the epigenetic state of oligodendrocyte precursors cells in multiple sclerosis (EPIScOPE)

Start date: Sep 1, 2016, End date: Aug 31, 2021,

Oligodendrocytes (OL) are glial cells that mediate myelination of neurons, a process that is defective in multiple sclerosis (MS). Although OL precursor cells (OPCs) can initially promote remyelination in MS, this regenerative mechanism eventually fails in progressive MS. OPCs go through several epigenetic states that ultimately define their potential to differentiate and myelinate. OPCs in progre...
Read Project

 1

 FINISHED 

Targeting oxidative repair proteins for treatment of cancer and inflammation (TAROX)

Start date: Aug 1, 2016, End date: Jul 31, 2021,

Oxidative damage and defects in DNA repair are frequently underlying many diseases, e.g., cancer, autoimmune diseases, ischemia/reperfusion injury, neurodegenerative disorders, viral diseases and ageing. Although some molecular understanding into oxidative DNA lesions and repair proteins exist, a thorough understanding on the link to diseases is largely missing, and therapies exploiting oxidative ...
Read Project

 1

 FINISHED 

Functional connectome of brainstem circuits that control locomotion (LocomotorIntegration)

Start date: Aug 1, 2016, End date: Jul 31, 2021,

Locomotion is a complex motor act that is used in many daily life activities and is the output measures of a plethora of brain behaviors. The planning and initiation of locomotion take place in the brain and brainstem, while the execution is accomplished by activity in neuronal networks in the spinal cord itself. Recent experiments have provided significant insight to the organization of the execu...
Read Project

 1

 FINISHED 

Understanding microbe-induced stomach cancer – the key to a workable strategy for worldwide prevention (PreventStoCan)

Start date: Jul 1, 2016, End date: Jun 30, 2021,

Stomach cancer is the 4th most common cancer and 2nd leading cause of cancer-related death worldwide. The aim of this proposal is to deepen the understanding of mechanisms involved in microbe-induced gastric carcinogenesis, which will facilitate risk stratification for identification of high-risk groups and may offer new opportunities for pharmacological and probiotic prevention. We hypothesize th...
Read Project

 1

 FINISHED 

Shaping of the Human Immune System by Primal Environmental Exposures In the Newborn Child (Born-Immune)

Start date: Jul 1, 2016, End date: Jun 30, 2021,

Immune systems are highly variable, but the sources of this variation are poorly understood. Genetic variation only explains a minor fraction of this, and we are unable to accurately predict the risk of immune mediated disease or severe infection in any given individual. I recently found that immune cells and proteins in healthy twins vary because of non-heritable influences (infections, vaccines,...
Read Project

 1

 FINISHED 

Therapeutic and Biomarker Potential of long non-coding RNAs in Vascular Disease (NORVAS)

Start date: May 1, 2016, End date: Apr 30, 2021,

The contribution of cardiovascular disease to human morbidity and mortality continues to steadily increase in our aging European society. In response, extraordinary efforts have been launched to determine the molecular and pathophysiological characteristics of its etiology. The collective work of multiple research groups has uncovered a complex transcriptional and post-transcriptional regulatory m...
Read Project

 1

 FINISHED 

RECAP: Research on European Children and Adults born Preterm (RECAP)

Start date: Jan 1, 2017, End date: Mar 31, 2021,

The project’s overall aim is to improve the health, development and quality of life of children and adults born very preterm (VPT, < 32 weeks of gestation) or very low birth weight (VLBW, < 1500g) – approximately 50 000 births each year in Europe – by establishing an ICT platform to integrate, harmonise and exploit the wealth of data from 20 European cohorts of VPT/VLBW children and adults and the...
Read Project

 21

 FINISHED 

Towards enduring mouse resources and services advancing research into human health and disease (INFRAFRONTIER2020)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society. The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is st...
Read Project

 33

 FINISHED 

Paediatric Clinical Research Infrastructure Network (PedCRIN)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

Children’s health is a major societal challenge for Europe and the world, requiring development of paediatric medicines and treatments strategies based on evidence derived from clinical trials demonstrating efficacy and safety in infants and children, rather than on uncritical extrapolation from adult data (over 50 % of the medicines used for children had not been tested in this specific age group...
Read Project

 16

 FINISHED 

Releasing the full potential of Instruct to expand and consolidate infrastructure services for integrated structural life science research (INSTRUCT-ULTRA)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

Instruct-Ultra aims to advance the scope and efficiency of implementation of Instruct and consolidate the foundations for long-term sustainability. This will be achieved through specific objectives: expand Instruct membership to new Member States and increase global links; engage new user communities; improve efficiencies in service delivery; improve data capture and management; adjust the scale a...
Read Project

 19

 FINISHED 

Implementation of cost-optimized childhood vision and hearing screening programmes in middle-income countries in Europe (EUSCREEN)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

Screening for vision and hearing disorders in children has shown to be highly effective. EU-directive 16620/11 invites EU-member states to give priority to such screening programmes. Early detection and treatment of a lazy eye (prevalence 3%) prevents lifelong visual impairment. Early detection and treatment of hearing impairment (prevalence 0.15%) prevents delayed speech and language development....
Read Project

 10

 FINISHED 

TRANSlating the role of Mitochondria in Tumorigenesis (TRANSMIT)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical eviden...
Read Project

 10

 FINISHED 

Comorbid Conditions of Attention deficit / hyperactivity disorder (CoCA)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

Understanding mechanisms underlying comorbid disorders poses a challenge for developing precision medicine tools. Psychiatric disorders are highly comorbid, and are among the last areas of medicine, where classification is driven by phenomenology rather than pathophysiology. We will study comorbidity between the most frequent psychiatric conditions, ADHD, mood/anxiety, and substance use disorders,...
Read Project

 17

 FINISHED 

European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur...
Read Project

 43

 FINISHED 

Boost Brittle Bones Before Birth (BOOSTB4)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe OI is affected throughout their lifetime with repeated, multiple fractures, considerable pain and handicap. There is no curative or effective treatment for OI. Our preclinical studies and initial clinical cases have demonstrated that transplantation of fetal m...
Read Project

 13

 FINISHED 

Molecular Tools for Nucleic Acid Manipulation for Biological Intervention (MMBio)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

MMbio will bridge the classically separate disciplines of Chemistry and Biology by assembling leading experts from academia and non-academic partners (industry, technology transfer & science communication) to bring about systems designed to interfere therapeutically with gene expression in living cells. Expertise in nucleic acid synthesis, its molecular recognition and chemical reactivity is combi...
Read Project

 13

 FINISHED 

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders (COSYN)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by...
Read Project

 14

 FINISHED 

Comprehensive characterization and effective combinatorial targeting of high-grade serous ovarian cancer via single-cell analysis (HERCULES)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

The goal of this multidisciplinary project is to comprehensively characterise high-grade serous ovarian cancer (HGS-OvCa) at single-cell level, identify the best combination of drug combination to kill HGS-OvCa populations and commercialise a predictive biomarker kit for finding the right therapeutic regimen to the right patient.This project takes an advantage on prospectively and longitudinally ...
Read Project

 9

 FINISHED 

RNA EDITING IN HEALTH AND DISEASE (RNAEDIT)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

"RNA editing is a type of programmed RNA sequence alteration that can result in a range of proteomic changes, from subtle fluctuations in output, to specific alterations in protein content. Editing is catalyzed by two classes of deaminases: those which convert adenosine to inosine (ADARs) and those which convert cytosine to uracil (APOBEC1). We have previously shown that APOBEC1-catalyzed editing ...
Read Project

 2

 FINISHED 

Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen (U-PGx)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and reduction in ‘trial and error’ prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and ...
Read Project

 16

 FINISHED 

Common mechanisms and pathways in Stroke and Alzheimer's disease. (CoSTREAM)

Start date: Dec 1, 2015, End date: Nov 30, 2020,

Common mechanisms and pathways in Stroke and Alzheimer's disease.It has long been recognized that stroke and (Alzheimer’s Disease) AD often co-occur and have an overlapping pathogenesis. As such, these two diseases are not considered fellow travelers, but rather partners in crime. This multidisciplinary consortium includes epidemiologists, geneticists, radiologists, neurologists with a longstandin...
Read Project

 11

 FINISHED 

Big data against childhood Obesity (BigO)

Start date: Dec 1, 2016, End date: Nov 30, 2020,

Childhood and adolescent obesity is a major global and European public health problem. Currently, public actions are detached from local needs, mostly including indiscriminate blanket policies and single-element strategies, limiting their efficacy and effectiveness. The need for community-targeted actions has long been obvious, but the lack of monitoring and evaluation framework and the methodolog...
Read Project

 14

 FINISHED 

European AIDS Vaccine Initiative 2020 (EAVI2020)

Start date: Nov 1, 2015, End date: Oct 31, 2020,

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradicati...
Read Project

 27

 FINISHED 

Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network (SYNTRAIN)

Start date: Sep 1, 2016, End date: Aug 31, 2020,

Breast and ovarian cancer constitute serious health challenges in the EU. To identify new improved cancer therapeutic approaches, we will pursue a multi-facetted synthetic lethal approach, which takes advantage of the inherent genetic instability of cancer cells. Most mutations acquired by cancer cells do not cause lethality, but the very same mutations may cause cell death when a second gene in a...
Read Project

 10

 FINISHED 

Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) (BRIDGES)

Start date: Sep 1, 2015, End date: Aug 31, 2020,

Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention or prophylactic surgery. Breast cancer risk is determined by a combination of genetic and lifestyle risk factors. The advent of next generation sequencing has opened up th...
Read Project

 20

 FINISHED 

Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes (B-CAST)

Start date: Sep 1, 2015, End date: Aug 31, 2020,

Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In combination, these variants can identify women at wide ranges of genetic risk, even in the absence of family history of breast can...
Read Project

 13

 FINISHED 

Prosaposin and GPR37 in synucleinopathies (PROGSY)

Start date: Aug 1, 2015, End date: Jul 31, 2020,

The next breakthrough in the treatment of synucleinopathies, incl Parkinson´s disease (PD), will be aimed at interference of disease progression based on insights into the underlying pathogenic process. The pathological hallmark of PD are Lewy bodies (LBs), in which α-synuclein is the major constituent together with other PD-linked gene products (DJ-1, LRRK2, parkin, and GBA) and aggregated GPR37....
Read Project

 1

 FINISHED 

Mechanisms of cellular fatty acid homeostasis (TGDNL)

Start date: Aug 1, 2017, End date: Jul 31, 2020,

The ability of cells to precisely maintain an internal steady state of lipids is essential for life. While homeostatic mechanisms controlling specific lipids such as sterols are well characterized, the regulation and coordination of fatty acid (FA) and triacylglycerol (TG) synthesis remains largely unknown. Several common metabolic disorders, including obesity and type 2 diabetes, lead to nonalcoh...
Read Project

 1

 FINISHED 

Revealing Allele-level Regulation and Dynamics using Single-cell Gene Expression Analyses (Allelic Regulation)

Start date: Jul 1, 2015, End date: Jun 30, 2020,

As diploid organisms inherit one gene copy from each parent, a gene can be expressed from both alleles (biallelic) or from only one allele (monoallelic). Although transcription from both alleles is detected for most genes in cell population experiments, little is known about allele-specific expression in single cells and its phenotypic consequences. To answer fundamental questions about allelic tr...
Read Project

 1

 FINISHED 

Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time (MDS-RIGHT)

Start date: May 1, 2015, End date: Apr 30, 2020,

Myelodysplastic syndromes (MDS) are chronic bone marrow malignancies of the elderly, complicated by severe anaemia. MDS significantly affects quality-adjusted survival and it imposes an increasing financial burden on patients and healthcare (HC) systems. The burden of disease is expected to worsen in the future, given the aging EU population and newly identified MDS cases among those diagnosed wit...
Read Project

 16

 FINISHED 

Validating C. elegans healthspan model for better understanding factors causing health and disease, to develop evidence based prevention, diagnostic, therapeutic and other strategies. (Ageing with elegans)

Start date: May 1, 2015, End date: Apr 30, 2020,

Healthspan (the life period when one is generally healthy and free from serious disease) depends on nature (genetic make-up) and nurture (environmental influences, from the earliest stages of development throughout life). Genetic studies increasingly reveal mutations and polymorphisms that may affect healthspan. Similarly, claims abound about lifestyle modifications or treatments improving healths...
Read Project

 20